Myocardial Infarction Clinical Trials 2023

What are the top hospitals conducting myocardial infarction research?

When it comes to cutting-edge clinical trials in the field of myocardial infarction, several top hospitals are making significant strides. The renowned Mayo Clinic, located in Rochester, has four active trials focused on this condition and a total of six completed studies. Since recording their first myocardial infarction trial in 2013, they have been at the forefront of research and innovation. Duke University Medical Center, situated in Durham, is another prominent institution that stands out with its four ongoing myocardial infarction trials and a remarkable twelve completed studies since their initial trial back in 2000.

The University of Pittsburgh Medical Center also plays a vital role in advancing our understanding of myocardial infarction. With four active clinical trials and an impressive seventeen previous studies under their belt since initiating research on this topic in 2006, they continue to contribute valuable insights into this life-threatening condition. On the west coast, Vancouver General Hospital boasts an equally notable record with four ongoing myocardial infarction trials and seventeen accomplished studies dating back to their first recorded trial in 2003.

Adding itself to this list is Reid Physician Associates based in Richmond where currently three active clinical inquiries are being taken place regarding myocardial infractions following along with completion of three similar investigations so far since only introduced such pioneering project last year during2020.

These esteemed institutions signify hope for individuals affected by heart attacks while serving as beacons for progress within the medical community at large. Their collective efforts bring us closer to breakthroughs that can improve treatment options and save lives worldwide

Which are the best cities for myocardial infarction clinical trials?

When it comes to myocardial infarction clinical trials, several cities show promise in advancing research and treatment. New York, with its 14 active trials, focuses on interventions like Liberal Transfusion Strategy, Enhanced Usual Care (EUC), and Orbital Atherectomy (OA). Edmonton, Alberta follows closely behind with 11 ongoing studies exploring strategies such as Liberal Transfusion Strategy, Implantable Cardioverter Defibrillator + Usual Care, and Restrictive Transfusion Strategy. Lastly, Atlanta, Georgia; Minneapolis, Minnesota; and Pittsburgh, Pennsylvania, Minnesont. New York, with its 14 active trials, focuses on interventions like Liberal Transfusion Strategy, Enhanced Usual Care (EUC), and Orbital Atherectomy (OA). Edmonton, Alberta follows closely behind with 11 ongoing studies exploring strategies such as Liberal Transfusion Strategy, Implantable Cardioverter Defibrillator + Usual Care, and Restrictive Transfusion Strategy. Lastly, Atlanta, Georgia; Minneapolis, Minnesota; and Pittsburgh, Pennsylvania each have 9 active trials investigating various approaches including Young Participants with Prior MI, Blood Transfusion strategies,and In-person cardiac rehabilitation. These cities provide patients with opportunities to participate in groundbreaking clinical trials for myocardial infarction that may shape the future of care.

Which are the top treatments for myocardial infarction being explored in clinical trials?

Clinical trials are paving the way for innovative treatments to combat myocardial infarction, also known as a heart attack. The top contenders in these trials include intervention and the Ellipsis Health Voice Application. Intervention is currently being explored in two active trials and has been listed since 2005, while the Ellipsis Health Voice Application shows promise with one ongoing trial since its debut in 2022. These cutting-edge approaches hold great potential for improving outcomes and transforming the landscape of myocardial infarction management.

What are the most recent clinical trials for myocardial infarction?

Promising developments in clinical trials offer hope for individuals affected by myocardial infarction, commonly known as a heart attack. Notably, the GXT+ THHR intervention has entered its Phase 2 trial stage and holds potential for improving outcomes after experiencing a heart attack. Another significant study involves Inclisiran Sodium 300mg in Phase 3, investigating its effectiveness in reducing the risk of future cardiac events following a myocardial infarction. Furthermore, research on Hemorrhagic Myocardial Infarction - Deferiprone is currently underway during Phase 1 to explore new avenues for treatment. Lastly, Evolocumab paired with routine lipid management is being evaluated in a Phase 4 trial to assess its impact on preventing recurring heart attacks. These recent clinical trials provide optimism for enhanced care and improved quality of life among those impacted by myocardial infarctions.

What myocardial infarction clinical trials were recently completed?

Recently completed clinical trials have made significant strides in the field of myocardial infarction research. In December 2020, R-Pharm Overseas successfully wrapped up a trial investigating the potential benefits of RPH-104 80 mg for patients with this condition. The University of Arkansas concluded their study on Aspirin 81 mg in November 2018, while the University of Maryland, Baltimore finished their investigation on Clopidogrel back in August 2017. These recent advancements offer valuable insights into potential therapeutic options and contribute to our understanding and management of myocardial infarction.